Key result
Renal stenting is linked to ~48% fewer major renal events in AI-identified delayed-perfusion phenotypes.
Why the study?
Does AI-based video-phenomapping of contrast-enhanced ultrasound predict major adverse renal events and identify patients who benefit from stenting in atherosclerotic renal artery stenosis?
Cohort (n=1,405)
Yes
Does AI-based video-phenomapping of contrast-enhanced ultrasound predict major adverse renal events and identify patients who benefit from stenting in atherosclerotic renal artery stenosis?
Answers are grounded in this paper and cite their sources.
AI-based video-phenomapping of renal microvascular hemodynamics identifies a specific 'Delayed' phenotype that benefits from stenting in atherosclerotic renal artery stenosis, while identifying therapeutic futility in 'Rarefied' phenotypes.
In middle-aged and older atherosclerotic renal artery stenosis (ARAS), the anatomical severity of stenosis is a poor surrogate for microvascular competence, and the renal benefit of revascularization is unpredictable. We developed Renal-Video-AI, a self-supervised deep learning framework (Video Swin Transformer with VideoMAE pretraining) that extracts spatiotemporal hemodynamic features from contrast-enhanced ultrasound, and applied it to a multi-center Discovery Cohort ( N = 1,226), an independent External Validation Cohort ( N = 122), a prospective Multimodal Cohort with paired 10x Visium spatial transcriptomics ( N = 57), and an aged two-kidney-one-clip (2K1C) murine model. Unsupervised phenomapping identified 3 intrinsic hemodynamic phenotypes—Preserved, Delayed, and Rarefied. The Rarefied phenotype predicted major adverse renal events (MAREs) independently of anatomical stenosis [hazard ratio (HR) 4.82, 95% confidence interval (CI) 3.10 to 6.50; Fine–Gray subdistribution HR (sHR) 5.1], and adding the phenotype to a standard clinical model improved the C-statistic from 0.72 to 0.88. A significant phenotype-by-treatment interaction ( P < 0.01) showed that stenting reduced events only in the Delayed phenotype (HR 0.52, 95% CI 0.35 to 0.78), not in the Preserved (HR 0.98) or Rarefied (HR 1.05) phenotypes. In absolute terms, stenting reduced the 3-year cumulative incidence of MARE in the Delayed phenotype from 25.4% to 13.2% (absolute risk reduction 12.2%; number needed to treat = 8, 95% CI 6 to 13), with no benefit in the Preserved (8.4% versus 8.0%) or Rarefied (38.6% versus 39.4%) phenotypes. Spatial transcriptomics localized a hypoxia and pyroptosis signature to rarefied tissue, and the aged 2K1C model revealed a mitochondrial reactive oxygen species (ROS)–NLRP3–pyroptosis axis whose pharmacological inhibition (MCC950) restored microvascular perfusion. AI video-phenomapping thus reframes the revascularization decision around microvascular competence rather than anatomy, identifying both therapeutic futility (Rarefied) and a treatable window (Delayed), and nominates NLRP3-driven pyroptosis as a therapeutic target.
No takes yet. Share an insight, caveat, or question.
Ju et al. (2026) conducted a cohort in Atherosclerotic renal artery stenosis (ARAS) (n=1,405). Stenting (in Delayed phenotype) vs. No stenting was evaluated on Major adverse renal events (MAREs) (HR 0.52, 95% CI 0.35 to 0.78, p=<0.01 for interaction). In patients with atherosclerotic renal artery stenosis, stenting reduced 3-year major adverse renal events in the AI-identified Delayed phenotype.
Synapse has enriched 10 related papers. Consider them for comparative context: